Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates
BOSTON and SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) ('Rapport' or the 'Company'), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today will host its inaugural Investor and Analyst Day, featuring presentations from Rapport's executive team on the Company's strategic priorities and updates from its clinical pipeline, including progress on the RAP-219 Phase 2a trial in focal epilepsy. The event's agenda also includes a fireside chat with key opinion leader and professor of Neurology at NYU Langone's Comprehensive Epilepsy Center, Jacqueline French, M.D., hosted by Rapport's Chief Medical Officer, Jeffrey Sevigny, M.D.
A livestream of the event and presentation materials will be available starting at 2:45 p.m. Eastern Time (ET) today and can be accessed by visiting 'News & Events' in the Investors section of the Company's website: https://investors.rapportrx.com.
'Our Phase 2a trial of RAP-219 in refractory focal epilepsy is now fully enrolled, and we remain on track to report topline results in September 2025,' said Abraham N. Ceesay, Chief Executive Officer of Rapport Therapeutics. 'This will mark a major milestone for our lead program and an opportunity to demonstrate the strength of our precision neuroscience approach. We're excited to share additional details about the trial ahead of the readout and honored to be joined by Dr. French, principal investigator of our RAP-219 epilepsy trial, who will provide valuable expert insight on the trial design and unmet need in focal epilepsy. Today's event allows us to further underscore the potential of RAP-219 as a differentiated therapeutic with broad clinical and commercial potential.'
Highlights of Rapport's Investor and Analyst Day event include the following:
Phase 2a trial of RAP-219 in refractory focal epilepsy
The Phase 2a trial of RAP-219 in refractory focal epilepsy is now fully enrolled. This proof-of-concept trial, designed with input from leading epilepsy experts, uses intracranial electroencephalography (iEEG) data from the RNS System to access RAP-219's potential effect on long episodes (LEs), an objective biomarker shown to correlate with clinical seizures (CSs).
Enrolled patients' baseline characteristicsPreliminary baseline characteristics of the first 14 patients enrolled—those for whom baseline data are available—indicate that the trial population is representative of patients historically enrolled in registrational refractory focal epilepsy trials.
Baseline Characteristics of First 14 Patients Enrolled
Median(range)
Median(1st to 4th quartile range)
Age
37 (20-61)
CS frequency per 28 days in 4-week prospective baseline
10 (4.25-18.25)
Sex (n)
7F/7M
LE frequency per 28 days in 12-week baseline (8-week retrospective + 4-week prospective)
51 (21-194)
Age at first seizure
19 (0.5-31)
Concordance between LEs and electrographic seizure (rated by an independent reviewer)
92% (71-96)
Years since RNS implantation
4.4 (1.4-10.2)
Concomitant antiseizure medications
3
Anticipated analysis of Phase 2a topline dataThe Company expects to provide the following data analysis when topline results are reported in September 2025:
Primary endpoint analysis:
Proportion of patients achieving ≥30% reduction in LEs compared with 12-week baseline period
Median percent change in LE frequency compared with 12-week baseline period
Key secondary endpoint analysis:
Median percent change in CS frequency compared with 4-week prospective baseline
Proportion of patients achieving ≥50% reduction in CSs compared with 4-week prospective baseline
Treatment-emergent adverse event (TEAE) incidence and grade
RAP-219 Phase 1 development update
Consolidated Phase 1 safety summary As disclosed in January, a total of four Phase 1 trials have been conducted—a single ascending dose trial, two multiple ascending dose trials, and a multiple ascending dose human positron emission tomography (PET) trial. Across these trials, 100 healthy volunteers have been exposed to RAP-219.
The Company's update includes data from the three completed Phase 1 multiple dose trials, including the PET trial from which final data were not available at the time of the Company's January disclosure. Final aggregate data (n=64) across the multiple dose trails continue to reinforce RAP-219's differentiated tolerability:
All TEAEs were Grade 1 or 2
No serious adverse events (SAEs), nor clinically significant laboratory, vital signs, or electrocardiogram (ECG) abnormalities
TEAEs occurred early in dosing and resolved without further action
Most common TEAEs: headache (n=12), dry mouth (n=5), brain fog (n=5), and fatigue (n=5)
Three discontinuations
Upcoming catalysts
September 2025: RAP-219 Phase 2a topline readout in focal epilepsy
Q3 2025: Initiation of RAP-219 Phase 2a trial in bipolar mania
2H 2025: Update on the Company's diabetic peripheral neuropathic pain program
1H 2027: RAP-219 Phase 2a topline readout in bipolar mania
Cash runway guidance
As of March 31, 2025, Rapport reported $285.4 million in cash, cash equivalents, and short-term investments, excluding restricted cash. These funds are expected to support operations through the end of 2026.
About RAP-219RAP-219 is a clinical-stage AMPA receptor (AMPAR) negative allosteric modulator (NAM) designed to achieve neuroanatomical specificity through its selective targeting of a receptor associated protein (RAP) known as TARPγ8, which is associated with neuronal AMPARs. Whereas AMPARs are distributed widely in the central nervous system, TARPγ8 is expressed only in discrete regions, including the hippocampus and neocortex, where focal seizures often originate. By contrast, TARPγ8 has minimal expression in the hindbrain, where drug effects are often associated with intolerable adverse events. With this precision approach, the Company believes RAP-219 has the potential to provide a differentiated profile as compared to traditional neuroscience medications. Due to the role of AMPA biology in various neurological disorders and the selective targeting of TARPγ8, the Company believes RAP-219 has pipeline-in-a-product potential and is evaluating the compound as a transformational treatment for patients with focal epilepsy, bipolar disorder, and peripheral neuropathic pain.
Availability of Other Information About Rapport TherapeuticsRapport Therapeutics uses and intends to continue to use its Investor Relations website and LinkedIn (Rapport Therapeutics) as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the Company's Investor Relations website and LinkedIn, in addition to following the Company's press releases, SEC filings, public conference calls, presentations, and webcasts. The contents of the Company's website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
About Rapport TherapeuticsRapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients with neurological or psychiatric disorders. The Company's founders have made pioneering discoveries related to the function of receptor associated proteins (RAPs) in the brain. Their findings form the basis of Rapport's RAP technology platform, which enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Rapport's precision neuroscience pipeline includes the Company's lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. The Company is currently pursuing RAP-219 as a potential treatment for refractory focal epilepsy, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.
Forward-Looking StatementsThis press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding: the clinical development of RAP-219 for the treatment of refractory focal epilepsy, bipolar mania and diabetic peripheral neuropathic pain, including the initiation, timing, progress and results of our ongoing and planned clinical trials; expectations for the activity, tolerability, and commercial potential of RAP-219; the potential of Rapport's RAP technology platform; and expectations for Rapport's uses of capital, expenses and financial results, including its cash runway through the end of 2026.
Forward looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect Rapport's business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to the Company's research and development activities; Rapport's ability to execute on its strategy including obtaining the requisite regulatory approvals on the expected timeline, if at all; uncertainties relating to preclinical and clinical development activities; the Company's dependence on third parties to conduct clinical trials, manufacture its product candidates and develop and commercialize its product candidates, if approved; Rapport's ability to attract, integrate and retain key personnel; risks related to the Company's financial condition and need for substantial additional funds in order to complete development activities and commercialize a product candidate, if approved; risks related to regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities; risks related to establishing and maintaining Rapport's intellectual property protections; and risks related to the competitive landscape for Rapport's product candidates; as well as other risks described in 'Risk Factors,' in the Company's Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in Rapport's subsequent filings with the Securities and Exchange Commission. Any forward-looking statements represent Rapport's views only as of today and should not be relied upon as representing its views as of any subsequent date. Rapport expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
ContactJulie DiCarloHead of Communications & IRRapport Therapeuticsjdicarlo@rapportrx.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
Lululemon Stock Is Beaten Down Now, But It Could 10X
Lululemon's revenue growth in North America should turn the corner soon. Its China and other international revenue has a lot of future potential for growth. The stock is trading at a cheap price, with management buying back shares. 10 stocks we like better than Lululemon Athletica Inc. › Recent years have been tough sledding for Lululemon Athletica (NASDAQ: LULU) investors. While the broad market indices are soaring, the apparel retailer's stock is down 20% cumulatively in the past five years -- and down 52% from all-time highs. Revenue growth has slowed significantly, with new competition entering the market amid slowing overall consumer spending on athleisure items. Pessimism has slowly crept into the share price, sending its price-to-earnings ratio (P/E) near a 10-year low. Despite this pain and underperformance, I believe Lululemon has a chance to 10x its stock for shareholders over the long haul. Here's why. In the first quarter of 2022, Lululemon's North America revenue grew 29% year over year. In Q1 2025, that figure has dipped to 4% on a constant currency basis. This is the key factor leading to Lululemon's falling stock price. Wall Street is highly concerned that the brand has reached saturation in the United States and Canada while facing stiff competition from upstart copycat brands. There may be some truth to new brands stealing some customers that would have instead gone to Lululemon, but the data doesn't support it being the majority reason for this huge revenue growth slowdown. Nike's revenue slipped 11% year over year last quarter, while Athleta's dipped 8%. Lululemon is growing while the competition is shrinking. That's why management stated that it gained share within its product category so far in 2025, which is categorized as premium athletic wear. So what is behind the revenue slowdown? In the pandemic and work-from-home peak, spending on athleisure apparel boomed, benefiting Lululemon. Now, that trend is partially reversing, which is affecting Lululemon's growth. Taking a longer view, more casual athleisure clothing has taken share from formal wear for decades. I expect this to continue once this pandemic reversion ends. As a market share taker in the category, Lululemon should be able to accelerate revenue growth in North America once this occurs. It is still a small player in the U.S. apparel market, which is estimated to have $359 billion in annual spending. The Americas are still 73% of Lululemon's net revenue, although the region is much smaller as a percentage of overall apparel sales globally. This gives Lululemon a clear path to grow internationally for years to come. Last quarter, China mainland revenue grew 22% year over year in constant currency to $368.1 million. This is just barely making a dent in the country's population of 1.4 billion people. At the same time, consumer spending in China has been hurt due to the collapse of a real estate spending bubble, which has affected popular international brands like Nike and Apple. Despite this, Lululemon's growth looks fantastic in China, which should be a positive signal for investors. Growth has been rock-solid in other markets, with revenue not in North America or China growing 17% year over year to $328 million. In areas like Australia, other Asian countries, and Latin America, Lululemon has plenty of room to grow its premium athleisure brand. Both China and the Rest of World segment should keep gaining as a percentage of Lululemon's overall revenue, which would be a tailwind to help reverse this slow revenue growth. Add up the potential of the North America, China, and Rest of World segments, and I believe Lululemon can generate consolidated double-digit revenue growth over the next decade, even though it only grew 8% on a constant currency basis last quarter. Today, Lululemon's revenue is just under $11 billion annually. Due to the factors discussed above, I think Lululemon's revenue can double or triple in the next 10 years. In order for the stock to 10x, we need some more factors to push the share price higher. For one, Lululemon has consistently raised the bar on its profit margins due to its pricing power in high-end athleisure. Tariffs on imports to the United States could pose a roadblock to this progress in the near term, but I see no reason why further scale won't lead to further profit margin expansion for the brand. Second, Lululemon is consistently repurchasing its outstanding shares at this cheap price. Its shares outstanding are down 6% in the last three years. This may not seem like much, but a steadily declining share count can be another way for the magic of compound interest to help boost stock returns, just with the compounding working in the negative direction. As Lululemon's shares outstanding keep coming down, its stock price should rise even more over the next 10 years. Lastly, Lululemon's shares are trading at a P/E ratio of 16.6, close to their lowest level in the last 10 years. As revenue growth accelerates, this earnings multiple should begin to normalize back to its long-term average, which will further juice stock returns. It won't occur because of any hypergrowth on the revenue line, but Lululemon can 10x for shareholders due to a combination of steady growth, margin expansion, share buybacks, and multiple expansion over the next 10 years. Before you buy stock in Lululemon Athletica Inc., consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Lululemon Athletica Inc. wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $699,558!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $976,677!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 30, 2025 Brett Schafer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Apple, Lululemon Athletica Inc., and Nike. The Motley Fool has a disclosure policy. Lululemon Stock Is Beaten Down Now, But It Could 10X was originally published by The Motley Fool Sign in to access your portfolio
Business Journals
an hour ago
- Business Journals
A financial look at Austin's 45 public companies
The 2025 list of Austin-area public companies is open to firms with local headquarters. The Austin area includes Travis, Williamson, Hays, Bastrop, Burnet and Caldwell counties. This year's list of Austin's 45 publicly held companies is down from last year's list of 56. A record-breaking fourteen firms left the list ––most by moving headquarters or mergers. Molecular Templates filed bankruptcy in May and Digital Brands Group was downgraded from the Nasdaq to OTCQX. A 46th public company, Victory Clean Energy, is not included because it has delayed filing its 2024 10(K) and related proxy. Five firms have joined the ranks, including SailPoint Technologies which IPOed for a second time in 2025 after being acquired and taken private in 2022. Other newcomers are MNTN, Monogram Technologies Inc., T1 Energy Inc. and Total Site Solutions (TSS) which moved from OTC to Nasdaq. Overall, the 45 listmakers have a combined revenue of $289 billion for their fiscal year ending in 2024. Dell's revenue dropped $14 billion and the companies that left the list took about $10 billion in revenue with them. Data is gathered from annual 10(K) and proxy reports as filed with the SEC. ABJ surveys these firms to update local employee count and current top executives.
Yahoo
an hour ago
- Yahoo
Raymond James Starts Coverage of Republic Bancorp (RBCAA) Stock with a Market Perform
Republic Bancorp, Inc. (NASDAQ:RBCAA) is one of the 10 Best Value Stocks to Buy According to Billionaires. On June 27, Raymond James began coverage of the company's stock with a 'Market Perform' rating and no price target, as reported by The Fly. As per the firm, the company is positioned for incremental growth over the upcoming years despite near-term EPS growth headwinds from lower income from the Tax Refund Solutions segment and modest NIM pressure. The analyst opines that the bank has been strategic in making itself a commercially focused community bank, catering to business and retail customers. A customer walking into a bank branch, expressing the convenience of consumer banking services. The firm also noted Republic Bancorp, Inc. (NASDAQ:RBCAA)'s consistent growth, superior capital levels, and improved profitability. Overall, the firm opines that the risk/reward profile for Republic Bancorp, Inc. (NASDAQ:RBCAA)'s stock remains balanced. The company's Tax Refund Solutions segment saw net income of $19.6 million during Q1 2025 as compared to net income of $8.8 million in Q1 2024. The rise was mainly aided by a positive $10.3 million decrease in the estimated Provision for RAs and Early Season RAs versus Q1 2024, and a 30% rise in the average per-unit profitability for Refund Transfers. While we acknowledge the potential of RBCAA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than RBCAA and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds' investor letters by entering your email address below. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
